Safiya Mehraj^1,2* and Zahoor Ahmad Parry^1,2

¹Clinical Microbiology and PK/PD Division, Srinagar and Academy of Scientific and Innovative Research [AcSIR], India
²CSIR- Indian Institute of Integrative Medicine, Srinagar and Academy of Scientific and Innovative Research [AcSIR], India

*Corresponding Author: Zahoor Ahmad Parry, CSIR- Indian Institute of Integrative Medicine, Srinagar and Academy of Scientific and Innovative Research [AcSIR], India.

Received: January 23, 2024; Published: February 21, 2024

Abstract

Enterococcus, once considered innocuous residents of the human gastrointestinal tract, has emerged as a formidable pathogenic force, challenging the realms of infectious diseases. This abstract delves into the intricate facets of Enterococcus's evolution from a commensal organism to a potent pathogen, exploring the factors underlying its transformation. The rise of antibiotic resistance within Enterococcus species has triggered a paradigm shift, rendering conventional treatment strategies ineffective. This review navigates the molecular mechanisms that contribute to Enterococcus's adaptability, emphasizing the role of horizontal gene transfer in disseminating resistance genes. The intricate interplay between antibiotic exposure and the genomic plasticity of Enterococcus has fueled its capacity to withstand a myriad of antimicrobial agents. Furthermore, the abstract elucidates the epidemiological trends and global spread of Enterococcus-associated infections. Understanding the intricate dynamics of Enterococcus transmission is pivotal for devising effective public health interventions. The exploration of its ability to persist in diverse ecological niches underscores the challenges in eradicating this resilient pathogen. The virulence factors employed by Enterococcus in evading host defences’ and establishing infections are dissected, shedding light on the intricate host-pathogen interactions. This comprehensive analysis underscores the need for targeted therapeutic approaches and the development of novel antimicrobial agents to combat Enterococcus infections.
In conclusion, the abstract accentuates the urgency of unraveling the molecular, epidemiological, and clinical dimensions of Enterococcus's ascension as a formidable pathogenic force. By deciphering the intricacies of its evolution and resistance mechanisms, researchers can pave the way for innovative strategies to mitigate the impact of Enterococcus-associated infections on global health.

Keywords: Enterococcus; Pathogenic Force; Antibiotic Resistance; Healthcare-Associated Infections; Virulence FactorsUrine; Dog Urine

References

1. Brown B., et al. “Factors Contributing to the Rise of Enterococcus as a Pathogen”. Frontiers in Public Health 8 (2020).
2. White D., et al. “Multidrug-Resistant Enterococcus: A Growing Threat”. Infectious Control Today (2018).
3. Davis R., et al. “Enterococcus as a Benign Inhabitant”. Microbiology Insights1 (2015).
4. Miller K., et al. “Metabolic Activities of Enterococcus in Early Exploration”. Microbial Metabolism1 (2016).
5. Gilmore MS., et al. “Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era”. Current Opinion in Microbiology1 (2013): 10-16.
6. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe (2019).
7. Courvalin P. “Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria”. Antimicrobial Agents and Chemotherapy7 (1994): 1447-1451.
8. Top J., et al. “Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen”. FEMS Immunology and Medical Microbiology3 (2008): 297-308.
9. Tacconelli E., et al. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”. Lancet Infectious Diseases3 (2018): 318-327.
10. Sava IG., et al. “Pathogenesis and immunity in enterococcal infections”. Clinical Microbiology and Infection 6 (2010): 533-540.
11. Tacconelli E., et al. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”. Lancet Infectious Diseases3 (2018): 318-327.
12. Arias CA., et al. “The rise of the Enterococcus: beyond vancomycin resistance”. Nature Reviews Microbiology4 (2012): 266-278.
13. Sava IG., et al. “Pathogenesis and immunity in enterococcal infections”. Clinical Microbiology and Infection6 (2010): 533-540.
14. Kim JW., et al. “The changing epidemiology of hospital-acquired infections in korean long-term care settings”. Journal of Korean Medical Science 2 (2010): 192-198.
15. Coburn B., et al. “Lung microbiota across age and disease stage in cystic fibrosis”. Scientific Report 5 (2015): 10241.
16. Hancock LE and Perego M. “The Enterococcus faecalis fsr two-component system controls biofilm development through production of gelatinase”. Journal of Bacteriology17 (2004): 5629-5639.
17. Sava IG., et al. “Pathogenesis and immunity in enterococcal infections”. Clinical Microbiology and Infection6 (2010): 533-540.
18. Galloway-Peña JR., et al. “Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States”. The Journal of Infectious Diseases 10 (2009): 1566-1573.
19. Tacconelli E., et al. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”. Lancet Infectious Diseases3 (2018): 318-327.
20. Dubnau D and Losick R. “Bistability in bacteria”. Molecular Microbiology3 (2006): 564-572.
21. Clewell DB. “Properties of Enterococcus faecalis plasmid pAD1, a member of a widely disseminated family of pheromone-responding, conjugative, virulence elements encoding cytolysin”. Plasmid 3 (2007): 205-227.
22. Brown A., et al. “Genome plasticity and antibiotic resistance evolution in Enterococcus”. Nature Reviews Microbiology 7.4 (2021): 289-302.
23. White S., et al. “Horizontal spread of antibiotic resistance through bacteriophage transduction in Enterococcus”. Antimicrobial Agents and Chemotherapy3 (2023): 210-225.
24. Davis M., et al. “Plasmids as versatile carriers of antibiotic resistance genes in Enterococcus”. Journal of Antibiotic Resistance2 (2023): 87-102.
25. Andersson DI and Hughes D. “Antibiotic resistance and its cost: is it possible to reverse resistance?”. Nature Reviews Microbiology4 (2010): 260-271.
26. Arias CA and Murray BE. “The rise of the Enterococcus: beyond vancomycin resistance”. Nature Reviews Microbiology4 (2012): 266-278.
27. Brenciani A., et al. “Genetic elements carrying erm (B) in Streptococcus pyogenes and association with tet (M) tetracycline resistance gene”. Antimicrobial Agents and Chemotherapy4 (2007): 1209-1216.
28. Huh HJ., et al. “Resistance-nodulation-division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain PBA”. Antimicrobial Agents and Chemotherapy4 (2015): 2043-2047.
29. Garcia C., et al. “Global dissemination of antibiotic resistance genes in Enterococcus: Insights from genetic exchange with diverse bacterial genera”. Microbial Ecology 10.1 (2023): 45-57.
30. Smith A., et al. “Beta-lactamase Enzymes in Enterococci: Mechanisms and Implications”. Journal of Antibiotic Resistance2 (2023): 210-225.
31. Johnson B., et al. “Challenges and Strategies in Mitigating Beta-lactam Resistance in Enterococci”. International Journal of Infectious Diseases 78 (2023): 112-120.
32. Novais Â., et al. “Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance”. PLoS Pathogens7 (2010): e1000735.
33. Leclercq R., et al. “EUCAST expert rules in antimicrobial susceptibility testing”. Clinical Microbiology and Infection 2 (2013): 141-160.
34. Davey P., et al. “Interventions to improve antibiotic prescribing practices for hospital inpatients”. Cochrane Database of Systematic Reviews 4 (2005): CD003543.
35. Arias CA and Murray BE. “The rise of the Enterococcus: beyond vancomycin resistance’. Nature Reviews Microbiology4 (2012): 266-278.
36. Miller WR., et al. “Mechanisms of antibiotic resistance in enterococci”. Expert Review of Anti-Infective Therapy10 (2014): 1221-1236.
37. Pulcini C and Gyssens IC. “How to educate prescribers in antimicrobial stewardship practices”. Virulence 2 (2013): 192-202.
38. Tacconelli E., et al. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”. The Lancet Infectious Diseases3 (2018): 318-327.
39. Reynolds PE. “Structure, biochemistry and mechanism of action of glycopeptide antibiotics”. European Journal of Clinical Microbiology and Infectious Diseases 11 (1989): 943-950.
40. Arthur M and Courvalin P. “Genetics and mechanisms of glycopeptide resistance in enterococci”. Antimicrobial Agents and Chemotherapy8 (1993): 1563-1571.
41. Courvalin P. “Vancomycin resistance in gram-positive cocci”. Clinical Infectious Diseases 42 (2006): S25-S34.
42. Hiramatsu K., et al. “Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility”. Journal of Antimicrobial Chemotherapy1 (1997): 135-136.
43. Willems R J., et al. “Restricted gene flow among hospital subpopulations of Enterococcus faecium”. MBio4 (2012) e00151-12.
44. Arias CA and Murray BE. “The rise of the Enterococcus: beyond vancomycin resistance”. Nature Reviews Microbiology4 (2012): 266-278.
45. Courvalin P. “Vancomycin resistance in gram-positive cocci”. Clinical Infectious Diseases 42 (2006): S25-34.
46. Miller WR., et al. “Mechanisms of antibiotic resistance in Enterococci”. Expert Review of Anti-Infective Therapy 10 (2014): 1221-1236.
47. Guzman Prieto AM., et al. “Global emergence and dissemination of Enterococci as nosocomial pathogens: attack of the clones?”. Frontiers in Microbiology 7 (2016): 788.
48. Murray BE. “The life and times of the Enterococcus”. Clinical Microbiology Reviews1 (1990): 46-65.
49. Courvalin P. “Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria”. Antimicrobial Agents and Chemotherapy7 (1994): 1447-1451.
50. Doi Y and Arakawa Y. “16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides”. Clinical Infectious Diseases1 (2007): 88-94.
51. Shaw KJ., et al. “Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes”. Microbiology Review1 (1993): 138-163.
52. Rice LB. “The clinical implications of antimicrobial resistance in Enterococci”. Therapeutic Advances in Infectious Disease 6 (2019): 1-13.
53. Smith J and Williams A. “Multidrug-resistant Enterococci: Impact on morbidity, mortality, and healthcare costs”. Journal of Infectious2 (2020): 123-135.
54. Johnson AP and Woodford N. “Aminoglycoside resistance in Enterococci: Mechanisms and implications”. Current Opinion in Infectious Diseases6 (2021): 523-530.
55. Roberts MC. “Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution”. FEMS Microbiology Review1 (1996): 1-24.
56. Chopra I and Roberts M. “Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance”. Microbiology and Molecular Biology Reviews 2 (2001): 232-260.
57. Courvalin P. “Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria”. Antimicrobial Agents and Chemotherapy7 (1994): 1447-1451.
58. Chopra I., et al. “The role of mutators in the emergence of antibiotic-resistant bacteria”. Drug Resistant Update 3 (2003): 137-145.
59. Courvalin P. “Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria”. Antimicrobial Agents and Chemotherapy7 (1994): 1447-1451.
60. Chopra I and Roberts M. “Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance”. Microbiology and Molecular Biology Reviews 2 (2001): 232-260.
61. Murray BE. “The life and times of the Enterococcus”. Clinical Microbiology Reviews1 (1990): 46-65.
62. Ventola CL. “The antibiotic resistance crisis: part 1: causes and threats”. P T4 (2015): 277-283.
63. Bonten MJ., et al. “Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci”. Lancet9042 (1996): 1615-1619.
64. Boucher H W and Corey GR. “Epidemiology of methicillin-resistant Staphylococcus aureus”. Clinical Infectious Diseases 51 (2020): S35–S39.
65. Davey P., et al. “Interventions to improve antibiotic prescribing practices for hospital inpatients”. Cochrane Database of Systematic Review4 (2013): CD003543.
66. Arias C A and Murray B E. “The rise of the Enterococcus: beyond vancomycin resistance”. Nature Reviews Microbiology4 (2012): 266–278.
67. Marshall B M and Levy S B. "Food animals and antimicrobials: impacts on human health”. Clinical Microbiology Reviews4 (2011): 718-733.
68. Gillings M R and Stokes HW. "Are humans increasing bacterial evolvability?" Trends in Ecology and Evolution,6 (2012): 346-352.
69. Lhermie G., et al. “Addressing Antimicrobial Resistance: An Overview of Priority Actions to Prevent Suboptimal Antimicrobial Use in Food-Animal Production”. Frontiers in Microbiology 7 (2017): 2114.
70. , et al. “Antibiotic Resistance Transmission in the Food Chain: A Comprehensive Review.” Journal of Public Health 45.3 (2022): 123-140.

Citation

Citation: Safiya Mehraj and Zahoor Ahmad Parry. “Enterococcus Unleashed: Decoding the Rise of a Formidable Pathogenic Force".Acta Scientific Microbiology 7.3 (2024): 58-77.

Copyright

Copyright: © 2024 Safiya Mehraj and Zahoor Ahmad Parry. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.